AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 251 min read$TEVA

Weiss Amir sold $355K of TEVA

Weiss Amir (Chief Accounting Officer) sold 9,445 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at an average of $37.62 ($37.61–$37.63, $0.36M total) across 2 trades on 2026-08-21.

Original reporting
SEC EDGAR · Weiss Amir
Published Aug 25, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TEVA
Neutral
high confidence
Mentioned
$TEVA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

Minimal impact; typical for routine insider sales of this magnitude.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential tax planning or portfolio rebalancing; not material to valuation.

Relevance 4/10Novelty 4/10Timing: filed today (2026-08-25)

Background

SEC Form 4 filing discloses insider transactions; used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$TEVANeutralHigh confidence
Context

Chief Accounting Officer Weiss Amir sold 9,445 shares for $355,301, reducing his stake to 13,071 shares.

Expected impact

Minor downward pressure, likely negligible.

Evidence & confidence

Sale size is modest relative to market cap; no broader implications.

Market effects

Sector

None; insider sale does not affect pharma sector broadly.

Regional

None; limited to TEVA shareholders.

Global

Low; isolated insider transaction.

Counterpoint

What could challenge this read

Sale could signal internal concerns, but size is too small to infer.

Key entities

  • Officer
    Weiss Amir

    Chief Accounting Officer of TEVA

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

SEP 4
$TEVAMed

S&P upgrades Teva rating on deleveraging and pipeline strength

S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd. to 'BBB-' from 'BB+', citing strong branded products, generics stabilization, and debt reduction. Teva's key brands generated $3.1B in 2025, with expected growth. The company reduced debt from $29B in 2018 to $17B in 2025 and aims for mid-3x leverage by year-end. S&P forecasts strong cash flow and debt reduction.

investing.com2 min
SEP 4
$TEVAMed

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

finance.yahoo.com3 min
SEP 4
$TEVAMed

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.

globenewswire.com1 min
SEP 2
$TEVAMedAI 8/10

Teva Stock Drops As Celiac Trial Fails To Impress - TipRanks.com

Teva Pharmaceutical's (TEVA) stock declined despite early-stage positive results from a Phase 2a trial of TEV-408 for celiac disease. Investors were unimpressed due to the lack of later-stage data or a commercialization timeline. The company is focusing on specialty medicines and biosimilars to stabilize growth but faces challenges from debt and generic revenue pressure.

tipranks.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial

Teva Pharmaceutical Industries' experimental drug TEV-53408 met its main goal in a mid-stage trial, preventing intestinal damage in celiac disease patients. The Phase 2a study showed significant improvement in intestinal health and symptom scores compared to placebo. Teva plans further studies and projects peak sales of $1.5B-$2B for the drug, which targets the IL-15 pathway. The company has a deal with Royalty Pharma for up to $500M in support.

medcitynews.com2 min